Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial

BACKGROUND: Activation of the TREM-1 pathway is associated with outcome in life threatening COVID-19. Data suggest that modulation of this pathway with nangibotide, a TREM-1 modulator may improve survival in TREM-1 activated patients (identified using the biomarker sTREM-1). METHODS: Phase 2 double-...

Descripción completa

Detalles Bibliográficos
Autores principales: François, Bruno, Lambden, Simon, Garaud, Jean-Jacques, Derive, Marc, Grouin, Jean-Marie, Asfar, Pierre, Darreau, Cédric, Mira, Jean-Paul, Quenot, Jean-Pierre, Lemarié, Jérémie, Mercier, Emmanuelle, Lacherade, Jean-Claude, Vinsonneau, Christophe, Fivez, Tom, Helms, Julie, Badie, Julio, Levy, Mitchell, Cuvier, Valérie, Salcedo-Magguilli, Margarita, Laszlo-Pouvreau, Anne-Lise, Laterre, Pierre-François, Gibot, Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231876/
https://www.ncbi.nlm.nih.gov/pubmed/37350989
http://dx.doi.org/10.1016/j.eclinm.2023.102013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231876/
https://www.ncbi.nlm.nih.gov/pubmed/37350989
http://dx.doi.org/10.1016/j.eclinm.2023.102013

Ejemplares similares